ArticleEClinicalMedicine2021

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.

Glenwood D Goss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.